Moderna, Inc. touted multiple development programs at its R&D day, but the event was not as positive as investors hoped as it also pushed back the timeline to becoming profitable, announced a large cut in R&D spending and reported a lack of enthusiasm from the US Food and Drug Administration for an accelerated approval filing of its Merck & Co., Inc.-partnered melanoma cancer vaccine.
Moderna Plans Big R&D Cut As Profitability Guidance Pushed Out
FDA Pushes Back On mRNA-4157 Accelerated Approval
The biotech saw its shares plunge more than 12% after an R&D day, where it announced it would push a breakeven target from 2026 to 2028.
